Wilms tumor
Drug research and approvals for wilms tumor: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 30 studies of wilms tumor are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 30
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With…NCT07796061 · Phase 1 · Children's National Research Institute · starts Dec 1, 2026
- FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaNCT07645469 · Phase 1 · Fred Hutchinson Cancer Center · starts Dec 1, 2026
- Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic…NCT07584499 · Phase 1 · Sun Yat-sen University · starts May 30, 2026
- Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)NCT07172958 · Phase 1 · Children's National Research Institute · starts Jan 27, 2026
- Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific…NCT07148050 · Phase 1 · Seattle Children's Hospital · starts Dec 22, 2025
- Physical Activity and Community EmPOWERment ProjectNCT06740162 · Not applicable · University of North Carolina, Chapel Hill · starts Jan 10, 2025
- Biomarkers of Resiliency In Childhood Cancer SurgeryNCT06674811 · Not reported · Mayo Clinic · starts Jan 15, 2025
- Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsNCT06625190 · Phase 1 / Phase 2 · University of Florida · starts Feb 11, 2026
- Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell TumorNCT06456359 · Phase 2 · University Hospital Heidelberg · starts Dec 19, 2024
Approved 1
- DactinomycinDNA inhibitor
Phase 3 3
- CyclophosphamideDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- VincristineTubulin inhibitor
Phase 2 7
- CarboplatinDNA inhibitor
- IfosfamideDNA inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- TopotecanDNA topoisomerase I inhibitor
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- PegfilgrastimGranulocyte colony stimulating factor receptor agonist
- Lorvotuzumab mertansineNeural cell adhesion molecule 1 binding agent
Phase 1 or earlier 3
- IsotretinoinRetinoic acid receptor agonist
- TemozolomideDNA inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
How its trials ended
125 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 18 whose ending is known, 33% met their primary endpoint, 11% missed it and 56% stopped early.
- Completed, result not reported6250%
- Ongoing3629%
- Status unknown97%
- Met its primary endpoint65%
- Stopped: other or unclear65%
- Stopped: enrollment or feasibility43%
- Missed its primary endpoint22%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA